期刊文献+

胰腺癌血清肿瘤标记物联合检测的临床研究 被引量:4

CLINICAL STUDY OF SERUM TUMOR MARKERS EXPESSION IN DIAGNOSIS AND PROGNOSIS OF PANCREATIC ADENOCARCINOMA
暂未订购
导出
摘要 目的 观察胰腺癌患者血清肿瘤标记物的表达 ,寻找对胰腺癌诊断与随访的有价值血清肿瘤标记物。方法 采用免疫分析法和放射免疫法检测 92例胰腺癌患者的血清 AFP、CEA、CA5 0、CA15 -3、CA19-9、CA72 -4、CA12 5和 CA2 42共 8种肿瘤标记物的表达 ,并与其它恶性肿瘤患者 70例和良性疾病患者 73例作对照 ,分析其临床诊断价值。结果  8种肿瘤标记物中 CA19-9、CA2 42、CA5 0和 CA12 5对胰腺癌诊断的相对价值较高 ,尤以 CA19-9的诊断价值最高 ,灵敏度和特异度分别为82 .6 %和 81.3% ,平行法联合检测提高灵敏度至 90 .2 % ,系列法联合检测提高特异度 93.5 % ,2 5例获手术切除者术后监测上述四项指标呈下降趋势。结论 血清 CA19-9、CA2 42、CA5 0和 CA12 5的检测对胰腺癌的诊断和随访是有价值的 。 Objective To search the valuable serum tumor markers in diagnosis and prognosis of pancreatic carcinoma.Methods 8 kinds of serum tumor markers including AFP,CEA,CA50,CA15 3,CA19 9,CA72 4,CA125 and CA242 were detected in 92 patients with pancreatic carcinoma by Auto DELFIA and IRMA and in 70 patients with other malignant tumors,73 benign disease patients.25 patients after pancreatectomy were followed up.Results Among eight kinds of tumor markers,CA19 9,CA242,CA50 and CA125 were valuable in diagnosis of pancreatic carcinoma.CA19 9 was the most valuable one,its sensitivity and specificity were 82.6% and 81.3% respectively.After resection of the tumor,the 4 markers tended to decrease signficantly.Conclusion Serum CA19-9,CA242,CA50 and CA125 were valuable in diagnosis and following up of pancreatic carcinoma.
出处 《肝胆外科杂志》 2001年第6期420-423,共4页 Journal of Hepatobiliary Surgery
关键词 血清肿瘤标记物 胰腺癌 联合检测 Serum tumor markers Pancreatic carcinoma
  • 相关文献

参考文献2

共引文献34

同被引文献27

  • 1谭欣诚,王云,张希成,刘志华.肝癌血清标志物联合检查的初步应用[J].临床荟萃,1997,12(4):178-178. 被引量:1
  • 2Sali F, Schlosser W, Falk enreck S et al. Prognostic Value of CA19-9 serum course in pancreatic cancer[J]. Hepato-Gastroenterology,1998,45:253.
  • 3Cappella. G, paladini S,D Agata A.I. marcatoritumorali nella diagnosidel carcinoma Pancreatico [Tumor markers in the diagnosis of pancreatic cancer][J].Tumori,1999,85(I suppl I):S19.
  • 4R Lamerz.Role of tomour markers, cytogeneticsncology 10suppl[J].Annals of oncology,1999,10suppl4:s:145.
  • 5Hayakawa T,Naruse S,Kitagawa M,et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases, Int J Pancreatol,1999,25:23-29.
  • 6Banfi G,Bravi S, Ardemagni A,et al. CA19-9,CA242 and CEA in the diagnosis and follow up of pancreatic cancer, Int J Biol Markers.1996,11:77 81.
  • 7Bornman PC, Beckingham IJ. Pancreatic tumours. BMJ,2001,322:721-723.
  • 8Giannini E,Borro P,Botta F,et al. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int J Biol Markers, 2000,15:226-230.
  • 9Kozuch P,Petryk M, Evans A, et al. Therapy for regionally unresectable pancreatic cancer. Surg Clin North Am ,2001,81 (3):691
  • 10Okada S, Yoshimori M, Kakizoe T. Pancreatic cancer: medical aspects. Pancreas, 1998,16 (7): 349

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部